Tag: clinical trials
-
Divergent CRO Announces Launch of New Contract Research Organization
ATLANTA, Ga. — Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the…
-
Pure Transplant Solutions Announces Collaboration with King’s College London to Support NHS Funded GAMECHANgER-1 Clinical Trial for HLA Sensitized Patients with End Stage Renal Disease
AUSTIN, Texas — Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with King’s College London.
-
Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients
AUSTIN, Texas — Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the “Spanish Society of Regenerative Medicine and Cell Therapy”), is pleased to announce the launch of a multicenter clinical trial, “The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure,”…
-
NED Biosystems Announces Leading Infectious Disease Research Scientist Michael Mansour, MD, PhD To Serve as Medical Advisor
CAMBRIDGE, Mass. — NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour, MD, PhD, will serve as the Company’s Medical Advisor of Infectious Disease.
-
A Novel Treatment Approach to Silent Hypoxia in COVID-19 Patients
PARK CITY, Utah — Silent Hypoxia is a frequent disabling and sometimes fatal complication in COVID-19 disease. To prevent SARS-CoV-2 coronavirus-induced damage to patients’ lungs and Silent Hypoxia in patients, Aristea Translational Medicine Corp. has initiated development of PhenT, a drug with novel cellular protective properties.
-
ROKiT Pharma’s Preclinical Studies Showing Tremendous Promise for Naturally Derived Cancer Drug, ROK-001 – Moving Towards The Initiation Of Phase 1b/2 Clinical Trial
LOS ANGELES, Calif. — ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.
-
iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting
STONY BROOK, N.Y. — iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of Hematology (ASH) Annual Meeting to…
-
CandyLipz Conducts Clinical Trial to Resolve Consumer Cupping Concerns
SAN FRANCISCO, Calif. — When some customers showed concern over cupping marks after using the lip plumper manufactured by CandyLipz, LLC, the company quickly jumped into action. It hired a third-party independent investigative research vendor, Biometrix, Inc. – a company that has conducted clinical trials for major multinational biotech, dermatology, product manufacturers and more for…